KennethWMahaffeyMD

PubMed

• Canagliflozin and iron metabolism in the CREDENCE trial.
  Akihiko Koshino, Hiddo J L Heerspink, Niels Jongs, Sunil V Badve, Clare Arnott
  Nephrology, Dialysis, Transplantation. 2025-04-01
• 3 citations
  Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
  Kenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, Florian M M Baeres, George Bakris
  European Heart Journal. 2025-03-24
• 1 citations
  The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.
  Tu N Nguyen, Jie Yu, Vlado Perkovic, Meg Jardine, Kenneth W Mahaffey
  Journal of the American Geriatrics Society. 2025-03-19

Journal Articles

• Alirocumab and Cardiovascular Outcomes After Acute Coronary Syndrome  
  Vera A Bittner, Kenneth W Mahaffey, Deepak L Bhatt, Robert A Harrington, Gregory G Schwartz, Matthew T Roe, The New England Journal of Medicine
• Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization  
  Kenneth Mahaffey, Manesh R Patel, W Schuyler Jones, William R Hiatt, Jeffrey S Berger, ScienceDirect
• Impact of Lesion Complexity on Peri-Procedural Adverse Events and the Benefit of Potent Intravenous Platelet Adenosine Diphosphate Receptor Inhibition After Percutaneo...  
  Gregg W Stone, Matthew J Price, Philippe Genereux, C Michael Gibson, Deepak L Bhatt, Robert A Harrington, Kenneth W Mahaffey, European Heart Journal
• Association of Healthcare Plan with Atrial Fibrillation Prescription Patterns  
  Andrew Young Chang, Paul A Heidenreich, Kenneth W Mahaffey, Clinical Cardiology
• Incremental Prognostic Value of Renal Function for Stroke Prediction in Atrial Fibrillation☆  
  Gregg C Fonarow, Kenneth W Mahaffey, Sean D Pokorney, Eric D Peterson, Jonathan P Piccini, International Journal of Cardiology
• Effects of Genetic Variation in Protease Activated Receptor 4 After an Acute Coronary Syndrome: Analysis from the TRACER Trial  
  Paolo Fortina, David J Moliterno, Robert A Harrington, Kenneth W Mahaffey, ScienceDirect
• Join now to see all

Lectures

• Shark Tank Judge 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• Effects of Canagliflozin on Heart Failure Outcomes With and Without Preserved Ejection Fraction in Type 2 Diabetes: Results From the CANVAS Program 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
• ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, With Lower Bleeding Risk 
  American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
• Results from the TRA•CER Trial 
  American Heart Association, Scientific Sessions 2011, Orlando, Florida, USA
• ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, With Lower Bleeding Risk 
  Scientific Sessions 2010, Chicago, Illinois, USA
• Results from the TRA•CER Trial 
  Scientific Sessions 2011, Orlando, Florida, USA
• Join now to see all